Envofolimab

DRUG2 trials

Sponsors

Jiangsu Simcere Pharmaceutical Co., Ltd., Sun Yat-sen University

Conditions

Advanced Biliary Tract CancerAdvanced Solid Tumor

Phase 2

A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

TerminatedNCT05148195

Jiangsu Simcere Pharmaceutical Co., Ltd.Advanced Solid Tumor

Start: 2021-12-22End: 2023-07-26Updated: 2024-03-13

Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)

Sun Yat-sen UniversityAdvanced Biliary Tract Cancer

Start: 2022-10-10End: 2025-08-01Target: 43Updated: 2022-10-12

Related Papers

Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.

2025-01-302 citations

The efficacy and safety of suvemcitug, envafolimab, and FOLFIRI in microsatellite-stable or mismatch repair-proficient colorectal cancer: preliminary results of a phase 2 study.

2025-01-21

Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study).

Journal of Clinical Oncology2024-06-011 citations